Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
7.59
-0.33 (-4.23%)
Oct 14, 2025, 3:27 PM EDT - Market open
Lyra Therapeutics Revenue
Lyra Therapeutics had revenue of $183.00K in the quarter ending June 30, 2025, a decrease of -69.40%. This brings the company's revenue in the last twelve months to $770.00K, down -57.69% year-over-year. In the year 2024, Lyra Therapeutics had annual revenue of $1.53M, down -1.54%.
Revenue (ttm)
$770.00K
Revenue Growth
-57.69%
P/S Ratio
13.59
Revenue / Employee
$25,667
Employees
30
Market Cap
12.47M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.53M | -24.00K | -1.54% |
Dec 31, 2023 | 1.56M | 195.00K | 14.31% |
Dec 31, 2022 | 1.36M | 1.08M | 378.25% |
Dec 31, 2021 | 285.00K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
LYRA News
- 8 days ago - Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - GlobeNewsWire
- 2 months ago - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 4 months ago - Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
- 4 months ago - Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
- 4 months ago - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewsWire
- 5 months ago - Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewsWire
- 5 months ago - Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire